NOVAVAX INC (NVAX)
Novavax, Inc. is a biotechnology firm dedicated to discovering, developing, and commercializing vaccines aimed at preventing serious infectious diseases and addressing critical health needs. The company's diverse pipeline includes NVX-CoV2373, a coronavirus vaccine candidate currently undergoing two Phase III trials, one Phase IIb, and one Phase I/II trial. Also featured is NanoFlu, a nanoparticle-based seasonal quadrivalent influenza vaccine in Phase 3 clinical trials. Furthermore, Novavax is advancing ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine, which is in Phase II clinical trials for adults aged 60 and older, and in Phase I for pediatric use. The company holds a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of its COVID-19 vaccine candidate, NVX-CoV2373. Established in 1987, Novavax, Inc. is headquartered in Gaithersburg, Maryland.
Sector: Biological Products, (No Diagnostic Substances)
Industry: Biotechnology
Novavax, Inc.
1-25 of 1,648 filings
Recent SEC filings with analysis
- 10-QNovavax reported Q3 2026 revenue of $68.3 million and a net loss of $31.4 million ($0.19 per share), a dramatic improvement from the year-ago quarter's $202.4…
- 8-KNovavax reported Q3 2026 total revenue of $68 million, down 3% year over year, with product sales of $26 million up 91% and net loss narrowing sharply to $31…